Moomoo AI 已提取核心信息
Cingulate Inc., a company listed in the United States, has received communication from the Securities and Exchange Commission (SEC) regarding its recently filed Registration Statement on Form S-1. The SEC, in a letter dated January 18, 2024, informed Cingulate's CEO Shane Schaffer that it has not reviewed and will not review the company's registration statement, which was filed on January 12, 2024. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures. The SEC's Division of Corporation Finance, Office of Life Sciences, directed any further questions to Daniel Crawford and provided his contact information.
Cingulate Inc., a company listed in the United States, has received communication from the Securities and Exchange Commission (SEC) regarding its recently filed Registration Statement on Form S-1. The SEC, in a letter dated January 18, 2024, informed Cingulate's CEO Shane Schaffer that it has not reviewed and will not review the company's registration statement, which was filed on January 12, 2024. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures. The SEC's Division of Corporation Finance, Office of Life Sciences, directed any further questions to Daniel Crawford and provided his contact information.
在美国上市的公司Cingulate Inc. 已收到美国证券交易委员会（SEC）关于其最近提交的S-1表格注册声明的来文。美国证券交易委员会在2024年1月18日的一封信中通知Cingulate首席执行官谢恩·沙弗，它尚未审查也不会审查该公司于2024年1月12日提交的注册声明。美国证券交易委员会的信中还提到了与加快注册程序的请求有关的第460和461条。此外，美国证券交易委员会提醒该公司及其管理层，他们有责任确保披露的准确性和充分性。美国证券交易委员会生命科学办公室公司财务处向丹尼尔·克劳福德提出了任何进一步的问题，并提供了他的联系信息。
在美国上市的公司Cingulate Inc. 已收到美国证券交易委员会（SEC）关于其最近提交的S-1表格注册声明的来文。美国证券交易委员会在2024年1月18日的一封信中通知Cingulate首席执行官谢恩·沙弗，它尚未审查也不会审查该公司于2024年1月12日提交的注册声明。美国证券交易委员会的信中还提到了与加快注册程序的请求有关的第460和461条。此外，美国证券交易委员会提醒该公司及其管理层，他们有责任确保披露的准确性和充分性。美国证券交易委员会生命科学办公室公司财务处向丹尼尔·克劳福德提出了任何进一步的问题，并提供了他的联系信息。
有用
没用